Fig 4 Artist's impression ofthe proposed Harwell treatment area
The patient is shown positioned horizontally with the head located in a stereotaxic frame to allow precise positioning of the pituitary gland in the beam (using two X-ray tubes for this alignment, one of which is pictured above the beam line). The head frame and bed can be rotated through 1800 to administer therapy through a number of portals on both sides of the head. In addition to the provisions for the treatment, due consideration has been given to the patient's comfort preceding and following treatment but these provisions are not described here. Summary This paper has described some physical properties of proton beams and their applicability to therapy. The similarity of the proton beams available from the Harwell and Harvard sychrocyclotrons has been stressed, and some details have been given of a proposal made to the Medical Research Council to use the Harwell synchrocyclotron for proton therapy by emulating the work of the Massachusetts General Hospital and Harvard University and by profiting, from their experience acquired over more than a decade.
In designing this facility we have also taken note of the use (Fowler 1972) of proton beam therapy for the treatment of other organs or malignances, as carried out at Harvard, Berkeley, Uppsala and Dubna, and have endeavoured to preserve the possibility of extending into these other areas.
Proposals for the use of proton, pion and heavy ion beams for therapy are becoming very prevalent at this time (Brookhaven National Labora-tory 1972, Los Alamos 1972) and although in this country therapeutic pion and heavy ion beams will not be available for some years the Harwell synchrocyclotron proton beams exist, they are reliable and they can be made available for therapy. A brief review was presented of the effects of irradiation upon survival of reproductive capacity of mammalian cells in vitro and in vivo. In the proton field distributions used for treatment of the pituitary fossa, the biological effects of this particle radiation would be expected to be little different from those of Xor y-rays (Berry 1971) . The major advantage of the proton beam compared with Xor y-ray beams was the relatively small dose delivered to surrounding normal structures due to scattered radiation (see Whitehead, p 29). Thus it is possible to deliver a dose to the centre of the pituitary fossa to kill all dividing cells, leaving a rim of pituitary gland sufficient to maintain pituitary functionthe decrease in excess pituitary function would be dependent upon the time which differentiated functional pituitary cells took to die.
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Published post-mortem evidence of late damage to the brain by proton beam irradiation was reviewed (Nielsen et al. 1972) ; only a mild astrocytosis and vascular reaction was seen at doses below 1000 rad. This would allow a central dose of 6000-10 000 rad to be delivered to the pituitary through a 10-field technique which was slightly simpler than that employed by Kjellberg et al. (1972) . This dose is somewhat less than that employed by Kjellberg, but is well within the effective doses for pituitary ablation quoted for irradiation with a deuteron beam by Lawrence et al. (1970) .
The Bragg peak of the proton beam has been used to treat 571 patients with pituitary-related disease. The method is associated with no mortality, low morbidity, short hospital stay and low cost.
Of the pituitary tumours, 254 procedures were done for acromegaly, 56 for Cushing's disease, and 44 chromophobe adenoma. The normal pituitary was irradiated in 183 instances for treatment of diabetic retinopathy and 35 procedures were done for carcinoma of the breast or prostate.
Normally, 12 portals of entry of beams are used on the two sides of the head, converging upon the sella turcica. The patient's head is secured in a stereotactic instrument applied under local anaesthesia with skeletal fixation. X-rays confirm the alignment of the proton 'beam spot' within the sella turcica. A beam diameter is selected for hyperfunctioning pituitary tumours to leave a shell of normal pituitary gland to preserve normal anterior and posterior lobe functions. Radionecrosis is induced in the central core of the tumour or gland. The dose along the beam path, for example, with a 10 mm beam diameter and 7000 rad to the pituitary tumour, is 300 rad, but most of the brain receives no radiation. The Bragg peak, the end of range of the proton beam, is about twice the path dose and stops within the pituitary. Measurements are made to fractions of a millimetre.
The entire procedure requires 1I to 2 hours during which time the patient is alert and cooperative. He walks away from the procedure and leaves the hospital the second day to return to home and occupation.
In acromegalics, mild headache is occasionally observed in the days following therapy. In 3 to 6 months, the patient's rings and heels of slippers become loose. In 6 to 12 months, the diminution in size of digits and facial features is obvious.
One year afterward the HGH may be 10 ng/ml, but it will probably fall further during the second year. Glucose intolerance becomes normalized. The patient often expresses gratification over his restoration of vitality and joie de vivre. He is less often impressed because he continues to preserve normal pituitary function. The prospect of recurrent acromegaly is not a problem.
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